It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
One SEC run, Two fluorescence readouts, highlighting the “Sygnature” peaks with your target protein.
Here we show how we have developed a much-improved Fluorescence-detection size-exclusion chromatography (FSEC) methodology that:
Uses less sample
Delivers unambiguous data to identify peaks containing a target protein in a complex mixture.
From a single chromatography run
With reduced run times
Background
We’ve used FSEC to assess membrane protein quality for years. After adding an HPLC with a fluorescence detector (FLD), the technique quickly became a go-to tool for both membrane and soluble targets.
For membrane proteins, FSEC lets us track a GFP-fusion directly in complex mixtures. We use the same selective fluorescence approach to follow labelled protein binders (including antibodies and nanobodies) in mixed samples for both FSEC and Fida studies.
For soluble proteins, the main impact is reduced sample consumption. Switching from standard 280 nm UV detection to intrinsic tryptophan fluorescence achieves a ~40-fold boost in signal.
The Challenge
Recently a client posed an interesting question: could we capture both readouts in a single experiment? They wanted the sensitivity and low sample consumption of intrinsic tryptophan fluorescence, and to unambiguously identify peaks from one labelled component in a complex mixture.
Options and Constraints
The straightforward workaround was to run each sample twice: once with the FLD tuned to tryptophan, and once to the dye signal (AlexaFluor 488). It would have delivered, but at the cost of doubling both sample consumption and instrument time.
There was one more constraint: our FLD module can’t switch between multiple excitation/emission pairs mid-run. However, if one wavelength is held constant, the other can be scanned – and with a small reduction in scan frequency we can record excitation or emission spectra during the method development phase.
Our Solution
Because many fluorophores share a region of non-selective UV excitation, we ran excitation wavelength scans to map the excitation profile of both fluorophores. This revealed a useful overlap in the low-UV region – one excitation wavelength that could drive both the Tryptophan and AlexaFluor 488 signals at the same time.
We then flipped the experiment and collected emission scans using that low-UV excitation. The result was exactly what we hoped for – characteristic emission spectra for each fluorophore. We could separate intrinsic protein signal from dye-labelled species in a single run.
With that in hand, we built a single-run FSEC method that reports both intrinsic and dye-labelled fluorescence. On the example chromatogram below, we could assign peaks 1-3 to unlabelled protein, peak 4 to dye-labelled protein, and peak 5 to unreacted dye – and we could do the peak assignment in real time.
Against the individually optimised settings, the combined method delivered a comparable response on the tryptophan channel, and a slight drop on the AlexaFluor 488 channel. Even so, sensitivity remained excellent: we obtained clean signals from as little as 2 µg/mL labelled protein – an injection of only 10 ng of labelled material.
Reducing the Run Time
Although we often use 30 cm SEC columns to maximise resolution, for this rapid method-development work we were grateful to Cytiva for the loan of a Superdex S200 5/150 column. This column can be a great option when high resolution isn’t essential – cutting run time and sample consumption to around a quarter of a standard 10/300 mm column.
Could Sygnature-FSEC Help Your Project?
Whether you’re interested in applying this approach to your target, or have a complex protein QC problem, contact us and see how our expert Protein Science team can help.